OSAKA - Takeda Pharmaceutical Company Limited (TOKYO: 4502/NYSE: TAK) announced today that it has announced that it will continue to conduct business for the full fiscal year 2023 (April 1, 2023 to March 31, 2024).

Although the fiscal year was significantly negatively affected by the expiration of the exclusive sales period, Core operating income achieved the full-year management guidance, which is the rate of increase/decrease on a CER basis, and sales revenue and Core EPS each exceeded the full-year management guidance. Ta.

In addition to continuing to exercise disciplined cost management, we will continue to expand growth and new products and advance up to six promising late-stage development programs to achieve our goal of improving core operating margins. Through this, we will realize business growth. Starting in fiscal 2024, we will implement a multi-year efficiency program that focuses on organizational agility, reducing procurement costs, and investing in data, digital and technology, including AI.

Christophe Weber, President and CEO of the company, said: 'Our 2023 results, including the U.S. FDA approval of three new products, demonstrate the promise of our pipeline and our ability to deliver innovative medicines to patients. 2023 will be a challenging year. However, the Core-based FY2023 performance reflects the resilience (flexible strength that does not succumb to adversity) required for the Company to return to sustainable revenue and profit growth from FY2025 onwards, as well as the It affirmed our confidence in our ability to mitigate the short-term impact of entry.

In 2024, up to six new candidate substances are scheduled to enter phase 3 clinical trials. Progressing these promising candidates into late-stage development while limiting R&D spending increases will require rigorous pipeline prioritization, increased efficiency, and organizational agility. Masu.

In addition, starting in fiscal 2024, we will implement a multi-year program to further improve efficiency through organizational mobility, cost reduction, and the use of data, digital, and technology. In addition to revenue growth from growing and new products and a significant reduction in the impact of generic entry, the program is expected to improve Core operating margin by 100 to 250 basis points annually starting in FY2025. We are looking forward to it. '

Our Chief Financial Officer, Miraino Furuta, said: 'We achieved or exceeded our full-year management guidance, which is the rate of change in sales revenue, Core operating income, and Core EPS on a CER basis, as growth products and new products continued to drive strong momentum. Earnings were impacted by the entry of generics into high-margin products, as well as strategic investments in research and development and data, digital and technology to strengthen long-term competitiveness.

Based on our progressive dividend policy and confidence in our long-term growth prospects and cash flow generation, we plan to increase our annual dividend for the second consecutive year, from 188 yen to 196 yen per share.

Revenue in FY2024 is expected to be flat to slightly decreasing on a CER basis, but revenue from growth products and new products is expected to grow at double-digit percentages on a CER basis, accounting for approximately 50% of total revenue. This is expected to reduce the impact of the continued entry of generic products. We expect the impact of further expiration of the exclusivity period to be limited from fiscal 2025 to the early 2030s, and from fiscal 2025 onwards, we will continue to focus on returning to sustainable growth in revenue and profits, thereby achieving long-term growth. I am confident that we can accomplish this.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) aims to contribute to the health and bright future of people around the world. Aiming to create innovative medicines in major disease areas and business areas such as gastrointestinal and inflammatory diseases, rare diseases, plasma-derived preparations, oncology, neuroscience, and vaccines. It is working. Together with our partners, we are working to build a strong and diverse pipeline to deliver new treatment options and contribute to improving the quality of life for patients. Takeda Pharmaceutical is a leading R&D-based biopharmaceutical company headquartered in Japan, based on its corporate philosophy of putting the patient at the center. Based on values that have been formed over more than two centuries, we are active in approximately 80 countries and regions in order to fulfill our purpose in society.

Forward-Looking Information

This news release and materials distributed in connection with this news release contain forward-looking information regarding Takeda's future business, future position and performance, including Takeda's estimates, forecasts, goals and plans; Contains ideas or opinions. Forward-looking information may be defined as 'targets,' 'plans,' 'believes,' 'hopes,' 'continues,' or 'expects.' ', 'aims', 'intends', 'ensures', 'will', 'may', 'should' 'should', 'would', 'could', 'anticipates', 'estimates', 'projects', 'predict' It often includes, but is not limited to, terms such as 'forecasts', 'outlook', similar expressions, or negative expressions thereof. These forward-looking information are based on assumptions regarding a number of important factors, and actual results may differ materially from any future results expressed or implied in the forward-looking information. Important factors include the economic conditions surrounding Takeda's global operations, including general economic conditions in Japan and the United States, the emergence and development of competitive products, changes in relevant laws and regulations, clinical success and the judgment of regulatory authorities. difficulties inherent in new product development, including uncertainties in the timing thereof; uncertainties in the commercial success of new and existing products; difficulties or delays in manufacturing; fluctuations in interest rates and exchange rates; products or candidates sold in the market; complaints or concerns regarding product safety or effectiveness; health crises such as the novel coronavirus pandemic; the success of Takeda's environmental and sustainability initiatives that enable us to reduce greenhouse gas emissions or achieve other environmental goals; Expected benefits include Takeda's efforts to improve operational efficiency, improve productivity or reduce costs, including the integration of digital technologies, including artificial intelligence (AI), and other business restructuring initiatives. Form 20 filed with the U.S. Securities and Exchange Commission , available on Takeda's website ( or -F's most recent annual report as well as other factors identified in Takeda's other reports. Takeda undertakes no obligation to update any forward-looking information contained in this news release or presented by Takeda, except as required by law or stock exchange regulations. Past performance is not a guide to future business results, and Takeda Pharmaceutical's business results and information in this news release are not indicative of, nor are any predictions, forecasts, or guarantees of Takeda Pharmaceutical's future business results. Or it is not an estimate.

Takeda Pharmaceutical's financial statements are prepared based on International Financial Reporting Standards.

This news release and the materials distributed in connection with this news release include Core revenue, Core operating income, Core net income, Core EPS, change on a CER (Constant Exchange Rate) basis, net interest-bearing debt, EBITDA, Contains financial measures that are not IFRS compliant, such as adjusted EBITDA and free cash flow. Our management evaluates our performance and makes operating and investment decisions based on IFRS and non-IFRS financial measures included in this news release. Non-IFRS financial measures exclude certain income, cost and cash flow items that would be included or have different values in the most closely matched IFRS financial measure. Non-IFRS-compliant financial measures are not IFRS-compliant, are in addition to, and are not a substitute for, IFRS-compliant financial measures (we refer to IFRS-compliant financial measures as 'financial-based' measures). (may be referred to as). Additionally, starting from the first quarter of 2024, Takeda will (i) change the CER adjustment method for the performance of subsidiaries located in hyperinflationary countries to ensure that their performance is consistent with IAS 29 'Financial Reporting in Hyperinflationary Economies'; In addition, (ii) the current free cash flow will be renamed to 'adjusted free cash flow' (in addition, the current free cash flow will be changed from cash flow from operating activities to cash flow related to the acquisition of property, plant and equipment). will be reported as 'free cash flow'). Please refer to the 'Financial Supplementary Materials' for further details regarding these changes, including their impact on fiscal 2023 results.

(C) 2024 Electronic News Publishing, source ENP Newswire